PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Observational study on antibody response to COVID-19 Vaccines in pAtients with gastro-entero-panCreatic Cancers and neuroendocrIne NeoplAsms on systemic TreatmEnts (VACCINATE).
Laffi, A.; Gervaso, L.; D’Ecclesiis, O.; Gandini, S.; Riva, A.; Passerini, R.; Spada, F.; Pellicori, S.; Rubino, M.; Cella, C.A.; Ravenda, P.S.; Zampino, M.G.; Fazio, N. Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE). Biomedicines2023, 11, 336.
Laffi, A.; Gervaso, L.; D’Ecclesiis, O.; Gandini, S.; Riva, A.; Passerini, R.; Spada, F.; Pellicori, S.; Rubino, M.; Cella, C.A.; Ravenda, P.S.; Zampino, M.G.; Fazio, N. Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE). Biomedicines 2023, 11, 336.
Laffi, A.; Gervaso, L.; D’Ecclesiis, O.; Gandini, S.; Riva, A.; Passerini, R.; Spada, F.; Pellicori, S.; Rubino, M.; Cella, C.A.; Ravenda, P.S.; Zampino, M.G.; Fazio, N. Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE). Biomedicines2023, 11, 336.
Laffi, A.; Gervaso, L.; D’Ecclesiis, O.; Gandini, S.; Riva, A.; Passerini, R.; Spada, F.; Pellicori, S.; Rubino, M.; Cella, C.A.; Ravenda, P.S.; Zampino, M.G.; Fazio, N. Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE). Biomedicines 2023, 11, 336.
Abstract
The Coronavirus disease-19 (COVID-19) pandemic dramatically impacted on oncologic patients' care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated also for oncologic population. However, data about the impact of anticancer-treatments and the timing between vaccinations and systemic therapy de-livery were not available. We aimed to evaluate potential factors influencing the outcome of COVID-19 vaccination in cancer patients.
We prospectively collected data of patients undergoing COVID-19 vaccination with gas-tro-entero-pancreatic and neuroendocrine neoplasms, treated at our Institute, between 03/2021 and 12/2021.
We enrolled 46 patients, 63.1% males; at the time of data collection 86.9% received two-doses of Pfizer-BioNTech and the remains Moderna vaccine. All patients obtained a subsequent im-mune-response. A significantly lower values of IgG for patients treated with chemotherapy versus other anti-cancer agents (p=0.004). No significant effect on immune-response was reported for both vaccinations performed ≤7 vs >7 days from the last systemic treatment (p=0.77) and lymphocytes count (p=0.11).
The findings suggest that the optimal timing for COVID-19 vaccination and lymphocytes count are not the issue but rather the quality of the subset of lymphocytes before the vaccination to deter-mine the efficacy level of immune-response in this population.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.